Frazier Healthcare Partners has led a $9.3m funding round in Penn spinout Scout Bio.
Scout Bio, a US-based gene therapy developer spun out from University of Pennsylvania, raised $9.3m in funding earlier this month in a round led by Frazier Healthcare Partners, the Philadelphia Inquirer reported today citing a regulatory filing.
Founded in 2016, Scout Bio is developing gene therapies reportedly aimed at companion animals, though the spinout remains in stealth mode and has not further indicated what it is working on.
The spinout’s board of directors include Kevin Mahoney, vice-dean of Penn’s…
